Format

Send to

Choose Destination
BMC Med Genet. 2013 Jun 14;14:61. doi: 10.1186/1471-2350-14-61.

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families.

Author information

1
Institute of Oncology, Riga Stradins University, Dzirciema Street 16, LV1007 Riga, Latvia.

Abstract

BACKGROUND:

The estimated ratio of hereditary breast/ovarian cancer (HBOC) based on family history is 1.5% in Latvia. This is significantly lower than the European average of 5-10%. Molecular markers like mutations and SNPs can help distinguish HBOC patients in the sporadic breast and ovarian cancer group.

METHODS:

50 patients diagnosed with HBOC in the Latvian Cancer Registry from January 2005 to December 2008 were screened for BRCA1 founder mutation-negatives and subjected to targeted resequencing of BRCA1 and BRCA2 genes. The newly found mutations were screened for in the breast and ovarian cancer group of 1075 patients by Real Time-PCR/HRM analysis and RFLP.

RESULTS:

Four BRCA2 mutations including three novel BRCA2 frameshift mutations and one previously known BRCA2 frameshift mutation and one BRCA1 splicing mutation were identified. Two of the BRCA2 mutations were found in a group of consecutive breast cancer patients with a frequency of 0.51% and 0.38%.

CONCLUSIONS:

Molecular screening of sequential cancer patients is an important tool to identify HBOC families.

PMID:
23767878
PMCID:
PMC3686592
DOI:
10.1186/1471-2350-14-61
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center